Surrozen (SRZN) Expected to Announce Earnings on Monday

Key Points

• Surrozen is expected to release its Q2 2025 earnings data on August 11th, with analysts projecting a loss of ($1.23) per share.
• The company's most recent earnings report indicated a loss of ($3.13) per share, missing estimates significantly, with revenue of $0.98 million.
• HC Wainwright maintained a "buy" rating for Surrozen, setting a price target of $32.00 for the stock.

Surrozen (NASDAQ:SRZN - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Surrozen to post earnings of ($1.23) per share for the quarter.

Surrozen (NASDAQ:SRZN - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($3.13) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by ($2.04). The business had revenue of $0.98 million for the quarter. On average, analysts expect Surrozen to post $-8 EPS for the current fiscal year and $-11 EPS for the next fiscal year.

Surrozen Price Performance

Shares of Surrozen stock traded up $0.35 during midday trading on Friday, hitting $9.38. 714 shares of the company were exchanged, compared to its average volume of 19,555. The firm has a 50 day simple moving average of $9.01 and a 200-day simple moving average of $9.89. Surrozen has a 52 week low of $5.90 and a 52 week high of $18.17. The firm has a market cap of $80.32 million, a P/E ratio of -0.38 and a beta of 0.60.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price on shares of Surrozen in a research note on Monday, May 12th.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.